Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
29 studies found for:    MAO-B
Show Display Options
Rank Status Study
1 Recruiting Detecting Central and Peripheral Biomarkers in MDD
Condition: Major Depressive Disorder
Intervention: Other: phenelzine treatment
2 Completed A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
Condition: Healthy Volunteer, Alzheimer's Disease
Interventions: Drug: 11C-L-deprenyl-D2;   Drug: RO4602522
3 Terminated MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Safinamide, MAO-B inhibitor;   Drug: Placebo
4 Recruiting Image Parkinson's Disease Progression Study
Condition: Parkinson's Disease
Interventions: Drug: Rasagiline;   Other: Placebo;   Device: Magnetic Resonance Imaging;   Device: functional Magnetic Resonance Imaging;   Other: Physical Function Performance Test
5 Completed Pharmacodynamic Profile of 'Blackadder' Blackcurrant Juice Effects Upon the Monoamine Axis in Humans
Conditions: Monoamine Oxidase Inhibitor Activity;   Prolactin Levels;   Postprandial Blood Glucose
Interventions: Dietary Supplement: Blackadder Juice;   Other: Placebo
6 Completed The Time Effects of a Berry Extract Upon Cerebral Blood Flow.
Condition: Cerebral Blood Flow
Interventions: Dietary Supplement: Berry drink;   Dietary Supplement: Control
7 Active, not recruiting Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
Condition: Parkinson's Disease
Intervention: Drug: Rasagiline
8 Completed Multi Dose Effects of a Berry Extract Upon Moodand Cognition in Healthy Young Adults
Condition: Healthy
Intervention: Dietary Supplement: Fresh berry extract.
9 Completed Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence
Condition: Smoking Cessation
Intervention:
10 Completed Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Condition: Parkinson's Disease
Intervention: Drug: Safinamide
11 Completed Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Safinimide 50-100 mg/day;   Drug: Matching Placebo
12 Not yet recruiting A Study to Evaluate the Efficacy of RO7046015 in Participants With Early Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: RO7046015;   Drug: Placebo
13 Completed Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease
Conditions: Sleep Disturbances;   Parkinsons's Disease
Interventions: Drug: Rasagiline;   Drug: Placebo
14 Completed
Has Results
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
Condition: Nicotine Dependence
Interventions: Drug: Nicotine Patch;   Drug: Moclobemide
15 Unknown  Rasagiline for Gait Treatment
Condition: Parkinson Disease
Intervention:
16 Terminated Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Rasagiline
17 Unknown  Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
Conditions: Drug-naïve Patients With Parkinson's Disease;   Apathy
Interventions: Drug: AZILECT®;   Drug: Placebo
18 Completed The Effect of Rasagiline on Cognition in Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: Rasagiline;   Drug: Placebo
19 Unknown  Effects of Chocolate on Motor Symptoms of Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Dietary Supplement: Chocolate
20 Completed Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Zelapar

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.